You are here

2012

Original articles

Schaefer M, Sarkar R, Weich V, Effenberg S, Friebe A, Heinze L, Spengler U, Schläpfer T, Reimer J, Buggisch P, Ockenga J, Link R, Rentrop M, Weidenbach H, Fromm G, Lieb K, Baumert TF, Heinz A, Discher T, Neumann K, Zeuzem S, Berg T. Escitalopram for the prevention of peginterferon alpha-2a and ribavirin-associated depression in HCV-infected patients (The CIPPAD study). Annals of Internal Medicine, 2012, 157, 94-103.

Fofana I*, Fafi-Kremer S*, Carolla P*, Fauvelle C, Zahid MN, Turek M, Heydmann L, Cury K, Hayer J, Combet C, Cosset FL, Pietschmann T, Hiet MS, Bartenschlager R, Habersetzer F, Doffoel M, Keck ZY, Foung SK, Zeisel MB, Stoll-Keller F, Baumert TF. Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. Gastroenterology, 2012, 143, 223-233.e9. *Authors contributed equally.

Dill MT, Makowska Z, Duong FH, Merkofer F, Filipowicz M, Baumert TF, Tornillo L, Terracciano L, Heim MH. Interferon gamma stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. Gastroenterology, 2012, 143, 777-786.

Fletcher NF, Wilson GK, Murray J, Hu K, Lewis A, Reynolds GM, Stamataki Z, Meredith LW, Rowe Ia, Luo G, Lopez-Ramirez MA, Baumert TF, Weksler B, Couraud PO, Kim KS, Romero IA, Jopling C, Morgello S, Balfe P, Mckeating JA. Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology, 2012, 142, 634-643.

Jo J, Bengsch B, Seigel B, Rau JS, Schmidt J, Bisse E, Aichele P, Aichele U, Joeckel L, Royer C, Sa Ferreira K, Borner C, Baumert TF, Blum HE, Lohmann V, Fischer R, Thimme R. Low perforin expression of early differentiated HCV-specific CD8+T cells limits their hepatotoxic potential. J. Hepatol., 2012, 57, 9-16.

Lacek K, Vercauteren K, Grzyb K, Naddeo M, Verhoye L, Slowikowski MP, Fafi-Kremer S, Patel AH, Baumert TF, Folgori A, Leroux-Roels G, Cortese R, Meuleman P, Nicosia A. Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. J. Hepatol., 2012, 57, 17-23.

Krepstakies M, Lucifora J, Nagel CH, Zeisel MB, Holstermann B, Hohenberg H, Kowalski I, Gutsmann T, Baumert TF, Brandenburg K, Hauber J, Protzer U. A new class of synthetic peptide inhibitors block attachment and entry of human pathogenic viruses. J. Infect. Dis., 2012, 205, 1654-64.

Florentin J, Aouar B, Dental C, Thumann C, Gondois-Rey F, Baumert TF, Dubreuil P, Nunes JA, Olive D, Hirsch I, Stranska R. HCV glycoprotein E2 is a novel BDCA-2 ligand and acts as an inhibitor of IFN production by plasmacytoid dendritic cells. Blood, 2012, 120, 4544-51.

Da Costa D*, Turek M*, Felmlee D*, Girardi E, Pfeffer S, Long G, Bartenschlager R, Zeisel MB#, Baumert TF#. Reconstitution of the entire hepatitis C virus life cycle in non-hepatic cells. J. Virol., 2012, 86, 11919-25. *Authors contributed equally, #authors contributed equally.

Molina-Jimenez F, Benedicto I, Loan Dao Thi V, Gondar V, Lavilette D, Marin JJG, Briz O, Moreno-Otero R, Aldabe R, Baumert TF, Cosset FL, Lopez-Cabrera M, Majano P. Matrigel-embedded 3D culture of Huh-7 cells as hepatocyte-like polarized system to study hepatitis C virus cycle. Virology, 2012, 425, 31-9.

Dental C, Florentin J, Aouar B, Gondois-Rey F, Durantel D, Baumert T, Nunes JA, Olive D, Hirsch I, Stranska R. Hepatitis C virus fails to activate NF-κB signaling in plasmacytoid dendritic cells. J. Virol., 2012, 86, 1090-6. (IF=4.64)
ACL 19.    Farquhar M, Hu K, Harris HJ, Davis C, Brimacombe CL, Fletcher SJ, Baumert T, Rappoport JZ, Balfe P, Mckeating J. Hepatitis C virus induces CD81 and claudin-1 receptor endocytosis: a role in particle internalization. J. Virol., 2012, 86, 4305-16.

Dao Thi VL, Granier C, Zeisel MB, Guerin M, Mancip J, Granio O, Penin F, Lavillette D, Bartenschlager R, Baumert TF, Cosset FL, Dreux M. Characterization of hepatitis C virus particle sub-populations reveals multiple usage of the scavenger receptor BI for entry steps. J. Biol. Chem., 2012, 287, 31242-57.

Guan M, Wang W, Liu X, Tong Y, Liu Y, Ren H, Zhu S, Dubuisson J, Baumert TF, Zhu Y, Peng H, Aurelian L, Zhao P, Qi Z. Three different functional microdomains in the hepatitis C virus hypervariable region 1 (HVR1) mediate entry and immune evasion. J. Biol. Chem., 2012, 287, 35631-45.

El-Andaloussi N, Bonifati S, Kaufmann JK, Mailly L, Daeffler L, Deryckère F, Nettelbeck DM, Rommelaere J, Marchini A. Generation of an adenovirus-parvovirus chimera with enhanced oncolytic potential. J. Virol., 2012, 86, 10418-31.

Reviews, editorials etc.

Lupberger J, Felmlee D, Baumert TF. Cholesterol uptake and hepatitis C virus entry. J. Hepatol., 2012, 57, 215-7.

Polyak SJ, Morishima C, Scott JD, Cox A, Stanislau E, Higgs M, Loo M, Mason LG, Lindenbach B, Baumert TF, Randall G, Pawlotsky JM, Gale M. A summary of the 18th International Symposium on Hepatitis C Virus and Related Viruses. Gastroenterology, 2012, 142, e1-5.

Barth H, Raghuraman S. Persistent infectious diseases say – IDO. Role of indoleamine-2-3-dioxygenase in disease pathogenesis and implications for therapy. Crit. Rev. Microbiol., 2012, 40, 360-8.

Lambotin M, Barth H, Moog C, Habersetzer F, Baumert TF, Stoll-Keller F, Fafi-Kremer S. Challenges for HCV vaccine development in HIV-HCV co-infection. Exp. Rev. Vaccines, 2012, 11, 791-804.

Fafi-Kremer S, Fauvelle C, Felmlee DJ, Zeisel MB, Lepiller Q, Fofana I, Heydmann L, Stoll-Keller F, Baumert TF.  Neutralizing antibodies and pathogenesis of hepatitis C virus infection. Viruses, 2012, 4, 2016-30.

Habersetzer F, Leboeuf C, Doffoël M, Baumert TF. Boceprevir and personalized medicine in hepatitis C virus infection. Pharmacogenomics Pers. Med., 2012, 5, 125-137.